Global Self Storage, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“On March 26, 2024, Global Self Storage, Inc. (the "Company") reported its financial results for the period ended December 31, 2023.”
Earnings Releases
Quarterly and annual results disclosed under 8-K Item 2.02.
US ENERGY CORP reported three and twelve months ended December 31, 2023 results: revenue $32.3 million.
“twelve months ended December 31, 2023 . FULL YEAR 2023 HIGHLIGHTS ● Total daily production in 2023 averaged 1,711 Boe/d; oil production averaged 1,073 Bbl/d. ● Revenue totaled $32.3 million with oil sales of $28.4 million and natural gas and liquids sales of $4.0 million. ● Lease operating expense of $15.3 million , or $24.43 per Boe, a 8% and 9% decrease ,”
Panbela Therapeutics, Inc. reported the quarter and full year ended December 31, 2023 results: net income Net loss in the fourth quarter of 2023 was $6.5 million, or $65.90 per diluted share, EPS $65.90 per diluted share.
“Net loss in the fourth quarter of 2023 was $6.5 million, or $65.90 per diluted share, compared to a net loss of $4.7 million, or $344.61 per diluted share, in the fourth quarter of 2022.”
IRIDEX CORP reported the year ended December 30, 2023 results: revenue $51.9 million.
“Revenue for the year ended December 30, 2023 was $51.9 million compared to $57.0 million in 2022.”
IRIDEX CORP reported the fourth quarter ended December 30, 2023 results: revenue $12.5 million, net income Net loss for the fourth quarter of 2023 was $3.0 million, EPS $0.18 per share.
“Revenue for the three months ended December 30, 2023 was $12.5 million compared to $15.2million during the same period of the prior year. Retina product revenue decreased 7% compared to the prior year period to $7.5 million. Total product revenue from the Cyclo G6 glaucoma product group was $3.0 million, a decrease of $1.2 million versus the fourth quarter of 2022. Other revenue decreased to $2.0 million in the fourth quarter of 2023 compared to the prior year period of $2.9 million, primarily driven by decreased royalties due to expiration of licensed patents and lower service revenue. Fourth quarter revenue was impacted by several factors. In the retina business, deferral of capital purchases led to lower system sales in the U.S. and internationally, international distributors destocked inventory in advance of new laser platform launches and to minimize any potential impact from transactions resulting from Iridex’s strategic review. The Company experienced isolated supply chain limit”
VOLITIONRX LTD reported the full fiscal year ended December 31, 2023 results: revenue approximately $775,000.
“· Cash and cash equivalents as of December 31, 2023, totaled approximately $20.7 million as compared to $10.9 million as of December 31, 2022. · Recorded approximately $775,000 in revenue in 2023, up 153% over the prior year. · Received $13.0 million in milestone payments from Heska Corporation in December 2023. · Net cash used in operating activities”
ASENSUS SURGICAL, INC. reported the fourth quarter and year ended December 31, 2023 results: revenue $8.6 million.
“growth of over 13% compared to 2022 ● In 2023, 8 Senhance Surgical Programs were initiated, which is in line with guidance of 8-10 systems ● Full year 2023 revenue of $8.6 million ● The Company had cash, cash equivalents and short-term investments, excluding restricted cash, of approximately $21.1 million at December 31, 2023 Fourth Quarter Highlights ●”
INTERLINK ELECTRONICS INC reported the three months and year ended December 31, 2023 results: revenue $3,538, net income $(448), EPS $(0.06).
“except per share data and percentages) Three Months Ended December 31, Year Ended December 31, Consolidated Financial Results 2023 2022 $ ∆ % ∆ 2023 2022 $ ∆ % ∆ Revenue $ 3,538 $ 1,611 $ 1,927 119.6 % $ 13,940 $ 7,493 $ 6,447 86.0 % Gross profit $ 1,452 $ 796 $ 656 82.4 % $ 6,559 $ 3,861 $ 2,698 69.9 % Gross margin 41.0 % 49.4 % 47.1 % 51.5 % Loss from”
Sanara MedTech Inc. reported the year ended December 31, 2023 results: revenue $65.0 million, net income net loss of $4.4 million.
“For the year ended December 31, 2023, Sanara generated net revenues of $65.0 million”
Sanara MedTech Inc. reported the quarter and year ended December 31, 2023 results: revenue $17.7 million, net income net loss of $0.3 million.
“outcomes and reduce costs throughout the U.S.” Strategic and Operational Highlights in the Fourth Quarter 2023 ● In the fourth quarter 2023, the Company generated a record $17.7 million in sales, representing a ninth record revenue quarter for the Company. ● For the three months ended December 31, 2023, the Company had a net loss of $0.3 million, compared to”
AMPCO PITTSBURGH CORP reported the twelve months ended December 31, 2023 results: revenue $422.3 million, net income $39.9 million, EPS $2.04 per share.
“U.S. forged business equipment modernization program in Q1 2024. Carnegie, PA, March 25, 2024 – Ampco-Pittsburgh Corporation (NYSE: AP)reported net sales of $108.1 million and $422.3 million for the three and twelve months ended December 31, 2023, compared to $93.5 million and $390.2 million for the three and twelve months ended December 31, 2022, respectively. The”
AMPCO PITTSBURGH CORP reported the three months ended December 31, 2023 results: revenue $108.1 million, net income $41.8 million, EPS $2.12 per share.
“Ampco-Pittsburgh Corporation (NYSE: AP)reported net sales of $108.1 million and $422.3 million for the three and twelve months ended December 31, 2023”
Smith Douglas Homes Corp. reported year ended December 31, 2023 results: revenue $764.6 million, net income $123.2 million.
“2,368 • Backlog homes increased 18.3% to 912 • Sales value of backlog homes increased 20.1% to $310.7 million • Home closings increased 4.4% to 2,297 • Revenue increased 1.2% to $764.6 million • Net income of $123.2 million, down 12.3% • Debt-to-book capitalization of 26.6% • Net-debt-to-net book capitalization of 21.1% 1 The Company had 69 active communities on”
Syra Health Corp reported full-year 2024 results: revenue $9 to $11 million. Guidance initiated.
“The Company expects full-year 2024 revenue of $9 to $11 million, representing a growth of 64%-100% versus 2023.”
Syra Health Corp reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $5.5 million, net income $(2.94 million). Guidance reaffirmed.
“and technology solutions, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2023. 2023 Financial Highlights ● 2023 revenue of $5.5 million compared to $5.6 million in 2022. ● Business units excluding Healthcare Workforce grew 250% and comprised 23% of total revenues in 2023, versus only 6% in 2022. ● Population”
Bitcoin Depot Inc. reported the year ended December 31, 2023 results: revenue $689.0 million, net income $1.6 million.
“by specific reference in such filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Bitcoin Depot Reports Fourth Quarter and Full Year 2023 Financial Results FY 2023 Record Revenue of $689 Million, Up 7% Year-over-Year FY 2023 Net Income of $1.6 Million, Down 54% Year-over-Year FY 2023 Record Adjusted EBITDA (non-GAAP) of $56 Million, Up 37% Year-over-Year Strengthens”
M-tron Industries, Inc. reported the fiscal year ended December 31, 2023 results: revenue $41.2 million, net income $3,489,000, EPS $1.28.
“year ended December 31, 2023 . Management will host an earnings call on Tuesday, March 26, 2024 at 10:30am EST. • Total revenues for the year ended December 31, 2023 , were $41.2 million, an increase of $9.3 million, or 29.3%, from $31.8 million for the year ended December 31, 2022. • Consolidated gross margin improved to 40.7% for the year ended December 31,”
Heliogen, Inc. reported fourth quarter and full year 2023 results: revenue $(1.2) million and $4.4 million, net income $(78.8) million and $(129.6) million.
“For the fourth quarter and full year 2023, Heliogen reported total revenue of $(1.2) million and $4.4 million, respectively, driven primarily by an unfavorable cumulative adjustment of $(3.4) million recorded during the fourth quarter of 2023, as a result of the updated Capella Project cost estimate. For the fourth quarter and full year 2023, Heliogen reported a net loss of $(78.8) million and $(129.6) million, respectively, driven primarily by the recognition of a non-cash provision for contract losses of $52.9 million, associated primarily with the change in estimate for its Capella Project.”
BuzzFeed, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.
“On March 25, 2024, BuzzFeed, Inc. (the “Company”), issued a press release (the “Press Release”) announcing its financial results for the fourth quarter and full year ended December 31, 2023.”
CATO CORP reported the full year of fiscal 2023 results: revenue $700.3 million, net income net loss of ($23.9) million, EPS ($1.17) per diluted share.
“2022, as the fiscal year ended February 3, 2024 contains 53 weeks versus 52 weeks in the fiscal year ended January 28, 2023. For the year, the Company's sales decreased 7% to $700.3 million from 2022 sales of $752.4 million. Same-store sales for the year decreased 6% compared to 2022. "Our fiscal 2023 sales trend was negatively impacted by pressure on our customers’”
CATO CORP reported the fourth quarter ended February 3, 2024 results: revenue $172.1 million, net income net loss of ($23.4) million, EPS ($1.14) per diluted share.
“expense is primarily due to a non-cash valuation allowance recorded against U.S. federal and state deferred tax assets. Sales for the fourth quarter ended February 3, 2024 were $172.1 million, or a decrease of 3% from sales of $177.5 million for the fourth quarter ended January 28, 2023. The Company’s same-store sales for the quarter decreased 5% compared to the same”
Bakkt, Inc. reported financial results for the quarter and year ended December 31, 2023.
“On March 25, 2024 , Bakkt Holdings, Inc. (the “Company”) issued a press release regarding the Company’s results for the quarter and year ended December 31, 2023.”
TMC the metals Co Inc. reported fourth quarter and full year ended December 31, 2023 results: net income Net loss of $33.5 million and net loss per share of $0.11 for the quarter ended December 31, 2023, EPS $0.11.
“On March 25, 2024, TMC the metals company Inc. (the “Company”) issued a press release announcing its results for the fourth quarter and full year ended December 31, 2023 and providing a business update.”
Jade Biosciences, Inc. reported the year ended December 31, 2023 results: net income $75.5 million.
“Net loss for the year ended December 31, 2023 was $75.5 million as compared to $51.5 million for the year ended December 31, 2022.”
Valion Bio, Inc. reported the year ending December 31, 2023 results: revenue $1.2M, net income net loss was $8.2M.
“and Global Health & Pharma (GHP) named Tivic Health the Most Pioneering Bioelectronic Medicine Company. 2023 Financial Performance • Revenue (net of returns) for 2023 was $1.2M compared to $1.8M for the year ended December 31, 2022. The decrease of $664 thousand, or 36%, was due to a 52% decrease in ClearUP unit sales, offset by 46% higher average”
Equillium, Inc. reported the fourth quarter and full year 2023 results: revenue $9.2 million.
“Revenue for the fourth quarter of 2023 was $9.2 million”
Rekor Systems, Inc. reported financial results for the fourth quarter and the fiscal year ended December 31, 2023.
“On March 25, 2024, Rekor Systems, Inc. (the “Company”) issued a press release summarizing the Company’s financial results for the fourth quarter and the fiscal year ended December 31, 2023.”
Stoke Therapeutics, Inc. reported the full year ended December 31, 2023 results: revenue $8.8 million, net income $104.7 million, or $2.38 per share, EPS $2.38 per share.
“Revenue recognized for upfront license fees and services provided from a License and Collaboration Agreement with Acadia Pharmaceuticals for the year ended December 31, 2023 was $8.8 million, compared to $12.4 million, for the year ended December 31, 2022.”
Sagimet Biosciences Inc. reported fourth quarter and year ended December 31, 2023 results: revenue $2.0 million.
“offering, are expected to fund operations for at least the next 12 months based on management’s current operating plan. · Revenues for the year ended December 31, 2023 were $2.0 million compared to no revenues for fiscal 2022. The increase was due to a $2.0 million milestone payment that was recognized in July 2023. · Research and development (R&D) expense for”
SUTRO BIOPHARMA, INC. reported the year ended December 31, 2023 results: revenue $153.7 million.
“stock on the last trading day of each reporting period, with any non-operating, unrealized gains and losses recorded in Sutro’s statements of operations. Revenue Revenue was $153.7 million for the year ended December 31, 2023, as compared to $67.8 million for the same period in 2022, with the 2023 amount related principally to the Vaxcyte manufacturing rights”
KIORA PHARMACEUTICALS INC reported financial results for the year ended December 31, 2023.
“Kiora Pharmaceuticals, Inc. (the "Company") issued a press release announcing financial results for the year ended December 31, 2023 and an update on clinical development progress.”
FENNEC PHARMACEUTICALS INC. reported financial results for full year and fourth quarter 2023.
“Fennec Pharmaceuticals Inc. issued a news release announcing full year and fourth quarter financial results for the period ended December 31, 2023.”
WORTHINGTON ENTERPRISES, INC. reported financial results for the three-month period ended February 29, 2024 (the Registrant’s fiscal 2024 third quarter).
“Registrant’s news release issued on March 20, 2024 (the “Financial News Release”) reporting results for the three-month period ended February 29, 2024 (the Registrant’s fiscal 2024 third quarter)”
ENERGY FOCUS, INC/DE reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue Net sales of $5.7 million, net income Net loss of $4.3 million, EPS $(1.32) per basic and diluted share of common stock.
“markets, today announced financial results for its fourth quarter and fiscal year ended December 31, 2023. Full-Year 2023 and Subsequent Business Highlights • Net sales of $5.7 million, down 4.2% from 2022, reflecting an increased military sales pipeline, superseded by decreasing commercial sales, and continuing fluctuations in the timing, pace, and size of”
TANDY LEATHER FACTORY INC reported fourth fiscal quarter and full year 2023 results: revenue $76.2 million, net income $3.8 million, EPS $0.23 per share.
“Tandy Leather Factory, Inc. (Nasdaq: TLF) today announced the Company’s financial results for the fourth fiscal quarter and full year 2023. Highlights from 2023: • Revenues were $76.2 million, down 5.1% from 2022 • Generated operating income of $4.4 million • Net income of $3.8 million, up from $1.2 million in 2022 • Gross margins of 59.3%, up from 57.9% in 2022 •”
AstroNova, Inc. updated its fiscal fourth quarter and full year ended January 31, 2024 guidance (initiated).
“On March 22, 2024, we issued a press release reporting the financial results for our fiscal fourth quarter and full year ended January 31, 2024.”
STAR EQUITY HOLDINGS, INC. reported the fourth quarter (Q4) and fiscal year (FY) ended December 31, 2023 results: revenue $14.1 million, net income $1.8 million, EPS $0.11 income per basic and diluted share.
“continuing operations, which currently include two divisions: Construction and Investments. Q4 2023 Financial Highlights vs. Q4 2022 (unaudited) • Revenues decreased by 19.8% to $14.1 million from $17.6 million. • Gross profit decreased by 47.0% to $2.9 million from $5.4 million. • Net income from continuing operations was $1.8 million (or $0.11 income per basic and”
PROKIDNEY CORP. reported financial results for the year ended December 31, 2023.
“ProKidney Corp. issued a press release to announce its financial results for the year ended December 31, 2023.”
REVELATION BIOSCIENCES, INC. reported twelve months ended December 31, 2023 results: net income net loss of $0.1 million, EPS $0.53 basic and diluted net loss per share.
“Revelation’s net loss for the three and twelve months ended December 31, 2023 was $2.2 million and $0.1 million, or $8.33 and $0.53 basic and diluted net loss per share, respectively”
REVELATION BIOSCIENCES, INC. reported three months ended December 31, 2023 results: net income net loss of $2.2 million, EPS $8.33 basic and diluted net loss per share.
“Revelation’s net loss for the three and twelve months ended December 31, 2023 was $2.2 million and $0.1 million, or $8.33 and $0.53 basic and diluted net loss per share, respectively”
HOOKIPA Pharma Inc. reported financial results for the fourth quarter and full year 2023.
“On March 22, 2024, HOOKIPA Pharma Inc. (the “Company”) announced Financial Results for the Fourth Quarter and Full Year 2023.”
Serina Therapeutics, Inc. reported financial results for fourth quarter and fiscal year ended December 31, 2023.
“On March 22, 2024, AgeX issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.”
Checkpoint Therapeutics, Inc. reported full-year ended December 31, 2023 results: net income Net loss attributable to common stockholders for the year ended December 31, 2023, was $51.8 million, EPS ($3.17 per share).
“Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights”
Moleculin Biotech, Inc. reported the fiscal year ended December 31, 2023 results: net income $29.8 million.
“Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today reported its financial results for the fiscal year ended December 31, 2023.”
GUGGENHEIM CREDIT INCOME FUND 2016 T reported financial results for for the year ended December 31, 2023.
“On March 22, 2024, Guggenheim Credit Income Fund 2016 T released an overview announcing its operating results for the year ended December 31, 2023, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.”
GUGGENHEIM CREDIT INCOME FUND 2019 reported financial results for the year ended December 31, 2023.
“On March 22, 2024, Guggenheim Credit Income Fund 2019 released an overview announcing its operating results for the year ended December 31, 2023, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.”
Xenetic Biosciences, Inc. reported the year ended December 31, 2023 results: net income approximately $4.1 million.
“Net loss for the year ended December 31, 2023 was approximately $4.1 million.”
Sow Good Inc. reported financial results for fourth quarter and full year ended December 31, 2023.
“On March 22, 2024, Sow Good Inc. (the " Company ") issued a press release announcing financial results for the year and three-months and year ended December 31, 2023.”
SANUWAVE Health, Inc. reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $7.0 million, net income $18.2 million. Guidance initiated.
“SANUWAVE Announces Record Q4 and FY2023 Revenue Q4 2023 revenues were a record $7.0 million, up 27% from Q4 2022 FY 2023 revenues were a record $20.4 million, up 22% from FY2022 Operating income was $1 million for Q4 2023 compared to an operating loss of $1.5 million for Q4 2022 Company provides guidance for revenue growth of 45-55% for Q1 2024 vs Q1 2023 and initiates annual guidance for FY2024 of 50% revenue growth vs. FY2023”
UNITED GUARDIAN INC reported FY 2023 results: revenue $10,885,154, net income $2,581,370 ($0.56 per share).
“Net sales for the year decreased by 14% from $12,698,503 in 2022 to $10,885,154 in 2023, generating net income of $2,581,370 ($0.56 per share) in 2023 compared to $2,569,512 ($0.56 per share) in 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.